Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylateresistant chronic myeloid leukemia patient

By          

Oncology Letters, Vol. 5, Iss. 5, 2013-01 ,pp. : 1579-1582

Spandidos Publications

Access to resources Recommend Favorite

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells

By          

International Journal of Oncology, Vol. 42, Iss. 2, 2013-01 ,pp. : 419-428

Spandidos Publications

Access to resources Recommend Favorite

Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia

By Al-Riyami Arwa Z.  

Leukemia and Lymphoma, Vol. 54, Iss. 8, 2013-08 ,pp. : 1788-1790

Informa Healthcare

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trichosanthin down-regulated p210^Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562

By Zhang Kunzhong   Xu Jianhua   Huang Xiuwang   Wu Lixian   Wen Caixia   Hu Yingying   Su Yu   Chen Yuanzhong   Zhang Zhiqiang  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 4, 2007-09 ,pp. : 581-587

Springer Publishing Company

Access to resources Recommend Favorite